Exchange & Returns Information
Review Details
(27)
| Drug Type | Original |
|---|---|
| Active Ingredient | TIRZEPATIDE |
| Strength | 10MG |
| Manufacturer | ELI LILLY AND COMPANY |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 1 PEN | $ 305.00 | $ 305.00 |
$ 256.20
Apply MOUN26 (-16%)
You save $ 48.80
|
||
| 2 BOXES - 2 PENS | $ 297.50 |
2% $ 610.00
$ 595.00
|
$ 499.80
Apply MOUN26 (-16%)
You save $ 95.20
|
||
| ★ Best Value 3 BOXES - 3 PENS | $ 291.67 |
4% $ 915.00
$ 875.00
|
$ 735.00
Apply MOUN26 (-16%)
You save $ 140.00
|
Reference information will be available soon.
Mounjaro 10mg is a once-weekly subcutaneous injection containing tirzepatide, a dual agonist that targets both GLP‑1 and GIP receptors. This dosage represents the third step in the titration sequence following 2.5mg, 5mg, and 7.5mg phases. It is designed for patients who have tolerated earlier doses and require enhanced glycemic control. Approved for the treatment of type 2 diabetes, this formulation supports both insulin secretion and delayed gastric emptying, contributing to improved HbA1c levels. Although weight loss is a well-documented secondary effect, this is not its primary approved indication—Zepbound is the weight-loss–specific formulation. The 10mg dose is widely recognized for balancing efficacy and tolerability, forming part of the individualized dose escalation path based on patient response.
- DIABETES (GLP-1 Receptor Agonists) > Used to improve blood glucose levels in adults with type 2 diabetes. The 10mg weekly dose is part of a progressive titration strategy and offers increased HbA1c reduction compared to earlier doses. It is often used in combination with oral antidiabetics or insulin for better glycemic control. - DIET (Metabolic Weight Control) > While not FDA-approved for obesity, tirzepatide shows significant weight-reducing effects even at 10mg. The impact is considered an adjunctive benefit in overweight or obese patients with type 2 diabetes, contributing to overall metabolic health. - LIFESTYLE-RELATED DISEASES (Obstructive Sleep Apnea – off-label) > In patients with moderate to severe obesity and OSA, weight loss from tirzepatide can indirectly reduce apnea-hypopnea index scores. Though Mounjaro is not approved for this use, its metabolic effects are being explored in off-label treatment combinations. - AntiCancer Drugs (Others – obesity-linked cancer modulation) > Early-phase research suggests potential benefits in reducing risks associated with obesity-related cancers, including breast cancer. This effect stems from its role in reducing systemic inflammation and insulin resistance—key drivers of metabolic-related malignancies.
Tirzepatide stimulates both GLP-1 and GIP receptors, which leads to enhanced insulin secretion, suppressed glucagon release, and delayed gastric emptying. The result is better glycemic control and increased satiety. Compared to GLP-1 receptor agonists alone, dual agonism has shown superior effects in HbA1c reduction and weight outcomes. The 10mg dose is often a turning point in the dose-escalation regimen, offering a strong balance between efficacy and gastrointestinal tolerability.
➔ Weekly Subcutaneous Injection (Type 2 Diabetes Indication): - Week 1–4: 2.5 mg SC once weekly (Initiation dose) - Week 5–8: 5 mg SC once weekly - Week 9–12: 7.5 mg SC once weekly - Week 13–16: 10 mg SC once weekly (This product) - Further escalation: 12.5 mg → 15 mg at 4-week intervals if needed ➔ Maintenance Range: 5–15 mg SC weekly based on clinical response and tolerability ➔ Maximum Dose: 15 mg per week ➔ Administration: - Administer in abdomen, thigh, or upper arm - Same time each week, with or without food - If missed: inject within 96 hours or skip until next scheduled dose ➔ Combination with Other Therapies: - Can be used with metformin, SGLT2 inhibitors, sulfonylureas, or basal insulin - Adjust insulin or sulfonylurea dosage to prevent hypoglycemia when starting tirzepatide ➔ Safety Considerations: - Contraindicated in individuals with a history of medullary thyroid carcinoma or MEN2 - Not suitable for type 1 diabetes or diabetic ketoacidosis - Monitor for pancreatitis, renal impairment, and worsening of diabetic retinopathy ➔ Off-Label Use Evidence: - 94% reduction in diabetes onset risk in prediabetic populations reported in early studies - Supports weight loss in OSA patients when used as metabolic adjunct - Potential anti-inflammatory role in obesity-related cancer and neurodegeneration prevention under investigation
Store unused pens refrigerated at 2–8°C Do not freeze After first use, pens may be kept at room temperature (below 30°C) for up to 21 days Keep away from direct sunlight and moisture Keep out of reach of children
Most common: nausea, vomiting, diarrhea, decreased appetite Others: constipation, abdominal pain, fatigue, dizziness, indigestion, injection site redness Serious risks: pancreatitis, gallbladder disorders, kidney problems, hypersensitivity reactions Caution with sulfonylureas or insulin due to hypoglycemia risk Seek medical attention if severe or persistent adverse effects occur
I prefer using cryptocurrency for online purchases, so I'm glad they offer this secure and private option.
My latest lab results were the best they've been in years. This medication has been truly life-changing.
The site is so easy to navigate. It makes the whole process of managing my prescription very pleasant.
What I appreciate most as a long-term customer is how this site respects my time. The user interface is so clean and efficient. I can log in, see my past orders, and reorder my 10mg Mounjaro pen with just a couple of clicks. There are no confusing menus or pop-ups. It's a brilliantly simple and professional user experience that makes managing my prescription completely stress-free.
マンジャロの治療を始めて4ヶ月、10mgの用量にステップアップしました。毎月の注文になりますが、このサイトはUIが非常に優れており、数クリックで再注文が完了するので全くストレスがありません。特に、毎回完璧な状態で届く冷蔵配送には、この薬局のプロ意識の高さを感じます。おかげで私は安心して治療に専念でき、健康状態も着実に改善しています。信頼できるパートナーを見つけられたことに心から感謝しています。
No combo deals available at the moment.
